KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biocryst Pharmaceuticals (BCRX) Accumulated Depreciation & Amortization (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 11.48% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2025, up 11.48%, and an annual FY2025 reading of $1.4 million, up 11.48% over the prior year.
  • Accumulated Depreciation & Amortization was $1.4 million for Q4 2025 at Biocryst Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.7 million in Q4 2023 and bottomed at $1.2 million in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 3 years is $1.4 million, with a median of $1.4 million recorded in 2025.
  • The sharpest move saw Accumulated Depreciation & Amortization decreased 24.71% in 2024, then increased 11.48% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.7 million in 2023, then decreased by 24.71% to $1.2 million in 2024, then grew by 11.48% to $1.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for BCRX at $1.4 million in Q4 2025, $1.2 million in Q4 2024, and $1.7 million in Q4 2023.